Deregulation of Polycomb Repressive Complex-2 in Mantle Cell Lymphoma Confers Growth Advantage by Epigenetic Suppression of cdkn2b
Christos Demosthenous(G. Papanikolaou General Hospital), Mamta Gupta(ICAR-Indian Institute of Maize Research), Shiv K. Gupta(Mayo Clinic), Yongsen Wang(Henan University), Tammy P. Troska(University of Minnesota Rochester), Jing Sun(Hangzhou Red Cross Hospital)
Cited by 7
Related Papers
Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts
|Clinical Cancer Research|2012|151
The Long Non-Coding RNA GAS5 Cooperates with the Eukaryotic Translation Initiation Factor 4E to Regulate c-Myc Translation
|PLoS ONE|2014|141
Gadd45a and Gadd45b Protect Hematopoietic Cells from UV-induced Apoptosis via Distinct Signaling Pathways, including p38 Activation and JNK Inhibition
|Journal of Biological Chemistry|2006|128
Delineation of<i>MGMT</i>Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma
|JNCI Journal of the National Cancer Institute|2015|122
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
|Journal of Hematology & Oncology|2019|108